

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – July 08, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
 - A. June 10, 2015 DUR Minutes – Vote
 - B. June 10, 2015 DUR Recommendations Memorandum
 - C. Correspondence

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – See Appendix B**
 - A. Medication Coverage Activity for June 2015
 - B. Pharmacy Help Desk Activity for June 2015
 - C. SoonerPsych Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Avycaz™ (Ceftazidime/Avibactam) and Zerbaxa™ (Ceftolozane/Tazobactam) – See Appendix C**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize to Prior Authorize Copaxone® (Glatiramer Acetate) 40mg/mL – See Appendix D**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Holderread, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Invega Trinza™ (3-Month Paliperidone Palmitate Injection) – See Appendix E**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Holderread, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Cholbam™ (Cholic Acid) – See Appendix F**
 - A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Holderread, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Natpara® (Parathyroid Hormone Injection) – See Appendix G

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Zenzedi® (Dextroamphetamine), Evekeo™ (Amphetamine), and Aptensio XR™ (Methylphenidate Extended-Release) – See Appendix H

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Xtoro™ (Finafloxacin) and Ofloxacin Otic – See Appendix I

- A. Ofloxacin Otic Solution Update
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Hetlioz® (Tasimelteon) and Belsomra® (Suvorexant) – See Appendix J

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

13. Annual Review of Antidepressant Medications and 30-Day Notice to Prior Authorize Irenka™ (Duloxetine) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Antidepressants
- C. Prior Authorization of Antidepressants
- D. Market News and Updates
- E. Irenka™ (Duloxetine) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Antidepressants

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. Annual Review of Alzheimer's Medications and 30-Day Notice to Prior Authorize Namzaric™ (Memantine Extended-Release/Donepezil) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Medications
- C. Prior Authorization of Alzheimer's Medications
- D. Market News and Updates
- E. Namzaric™ (Memantine Extended-Release/Donepezil) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Alzheimer's Medications

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

15. 30-Day Notice to Prior Authorize Corlanor® (Ivabradine) – See Appendix M

- A. Introduction
- B. Corlanor® (Ivabradine) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

16. Annual Review of Opioid Analgesics & Buprenorphine Products and 30-Day Notice to Prior Authorize Hysingla® ER (Hydrocodone Bitartrate Extended-Release) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics & Buprenorphine Products
- C. Prior Authorization of Opioid Analgesics & Buprenorphine Products
- D. Opioid Analgesic Utilization Trends

- E. Market News and Updates
- F. Hysingla® ER (Hydrocodone Bitartrate Extended-Release) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Opioid Analgesics and Buprenorphine Products

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

17. 30-Day Notice to Prior Authorize Various Special Formulations: Sitavig® (Acyclovir Buccal Tablets), Rasuvo® (Methotrexate Injection), Otrexup™ (Methotrexate Injection), Onmel™ (Itraconazole Oral Tablets), & Purixan® (Mercaptopurine Oral Suspension) – See Appendix O

- A. Introduction
- B. Product Summaries
- C. College of Pharmacy Recommendations

Non-Presentation, Questions Only:

18. Annual Review of Growth Hormone – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Growth Hormone
- C. Prior Authorization of Growth Hormone
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Growth Hormone

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

19. FDA and DEA Updates – See Appendix Q

Items to be presented by Dr. Muchmore, Chairman:

20. Adjournment